ArticleNPJ breast cancer2018

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Daniel G Stover et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.